2021
Effects of MTX-23, a Novel PROTAC of Androgen Receptor Splice Variant-7 and Androgen Receptor, on CRPC Resistant to Second-Line Antiandrogen Therapy
Lee G, Nagaya N, Desantis J, Madura K, Sabaawy H, Kim W, Vaz R, Cruciani G, Kim I. Effects of MTX-23, a Novel PROTAC of Androgen Receptor Splice Variant-7 and Androgen Receptor, on CRPC Resistant to Second-Line Antiandrogen Therapy. Molecular Cancer Therapeutics 2021, 20: 490-499. PMID: 33277442, DOI: 10.1158/1535-7163.mct-20-0417.Peer-Reviewed Original ResearchConceptsCastration-resistant prostate cancerSecond-line antiandrogen therapyAR full lengthAndrogen receptor splice variant 7AR-V7Antiandrogen therapyAndrogen-responsive prostate cancer cellsProstate cancer cellular proliferationHuman prostate cancer cell linesProstate cancer cell linesStandard of careCancer cellular proliferationCellular proliferationPotential therapeutic valueProstate cancer cellsAgents abirateroneCancer cell linesProteolysis Targeting ChimerasMechanisms of resistanceAndrogen receptorAR DNAProstate cancerTumor growthTherapeutic valueAntiproliferative effects
2019
TCF4 induces enzalutamide resistance via neuroendocrine differentiation in prostate cancer
Lee G, Rosenfeld J, Kim W, Kwon Y, Palapattu G, Mehra R, Kim W, Kim I. TCF4 induces enzalutamide resistance via neuroendocrine differentiation in prostate cancer. PLOS ONE 2019, 14: e0213488. PMID: 31536510, PMCID: PMC6752758, DOI: 10.1371/journal.pone.0213488.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBenzamidesBeta CateninCell Line, TumorDisease Models, AnimalDrug Resistance, NeoplasmHumansMaleMiceMice, KnockoutNeuroendocrine CellsNitrilesPhenylthiohydantoinProstatic NeoplasmsProtein BindingProtein TransportTranscription Factor 7-Like 2 ProteinXenograft Model Antitumor AssaysConceptsCastration-resistant prostate cancerEnzalutamide resistanceTranscription factor 4Neuroendocrine differentiationProstate cancerSecond-generation androgen receptor antagonistHuman prostate cancer cell linesLNCaP human prostate cancer cell lineResistant prostate cancerProstate cancer cell linesStandard of careAndrogen receptor antagonistMouse xenograft modelExpression levelsCell linesTCF4 overexpressionCancer cell linesMedian timeClinical benefitReceptor antagonistNeuroendocrine markersMetastatic CaPTreatment resistanceXenograft modelParental cell line
2013
Mechanism of pro‐tumorigenic effect of BMP‐6: Neovascularization involving tumor‐associated macrophages and IL‐1α
Kwon S, Lee G, Lee J, Iwakura Y, Kim W, Kim I. Mechanism of pro‐tumorigenic effect of BMP‐6: Neovascularization involving tumor‐associated macrophages and IL‐1α. The Prostate 2013, 74: 121-133. PMID: 24185914, DOI: 10.1002/pros.22734.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBone Morphogenetic Protein 6CarcinogenesisCell DifferentiationCell Line, TumorCell ProliferationCoculture TechniquesEndothelium, VascularHumansInterleukin-1alphaMacrophagesMaleMiceMice, Inbred C57BLMice, KnockoutNeovascularization, PathologicNF-kappa BProstatic NeoplasmsSignal TransductionSmad1 ProteinConceptsBone morphogenetic protein 6Prostate cancer growthTumor-associated macrophagesIL-1APro-tumorigenic effectsCancer growthHuman prostate cancer cell linesHuman prostate cancer tissuesLNCaP human prostate cancer cell lineProstate cancer cell linesTube formationProstate cancer tissuesTHP-1 cellsEndothelial tube formationCancer cell linesIL-1αProstate cancerKnockout miceCD11b-DTRCancer tissuesTumor growthNF-kB1Endothelial cellsMacrophagesConditioned media
2012
CREBZF, a novel Smad8-binding protein
Lee J, Lee G, Kwon S, Jeong J, Ha Y, Kim W, Kim I. CREBZF, a novel Smad8-binding protein. Molecular And Cellular Biochemistry 2012, 368: 147-153. PMID: 22707059, DOI: 10.1007/s11010-012-1353-4.Peer-Reviewed Original ResearchConceptsSmads 1Novel SmadTranscription factorsBMP-6Basic region-leucine zipper (bZIP) transcription factorsBone morphogenetic protein (BMP) pathwayRegulation of SmadTwo-hybrid screeningModulation of BMPBMP response elementZipper transcription factorTGF-β signal pathwayR-SmadsReceptor SmadsBMP pathwaySecondary messengersPromoter activityLigand bindingProtein pathwayResponse elementProstate cancer cell linesCell growth inhibitionHuman prostate cancer cell linesSmadSignal pathway
2004
Loss of expression of bone morphogenetic protein receptor type II in human prostate cancer cells
Kim I, Lee D, Lee D, Ahn H, Kim M, Kim S, Morton R. Loss of expression of bone morphogenetic protein receptor type II in human prostate cancer cells. Oncogene 2004, 23: 7651-7659. PMID: 15354178, DOI: 10.1038/sj.onc.1207924.Peer-Reviewed Original ResearchConceptsBone morphogenetic proteinProstate cancer cellsHuman prostate cancer cellsLoss of expressionProstate cancer patientsBMP-RIICancer patientsGleason scoreBMP receptor type IABone morphogenetic protein receptor type IICancer cellsSignificant associationHuman prostate cancer cell linesBiochemical recurrence-free rateExpression of BMPRsRecurrence-free rateProstate cancer cell linesCell linesTumor growth rateReceptor type IIParental cell lineCancer cell linesMorphogenetic proteinsClinical stagePrognostic value
2002
Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines.
Kim I, Kim B, Seong D, Lee D, Seo J, Hong Y, Kim H, Morton R, Kim S. Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines. Cancer Research 2002, 62: 5365-9. PMID: 12235008.Peer-Reviewed Original ResearchConceptsAndrogen-independent human prostate cancer cell linesMixed estrogen agonist/antagonistProstate cancer cell linesHuman prostate cancer cell linesEstrogen agonist/antagonistAgonists/antagonistsCancer cell linesER betaER alphaCell linesDU145 cellsSelective estrogen receptor modulatorsEffects of raloxifeneEstrogen receptor modulatorsPC3M cellsDose-dependent mannerCell deathM raloxifeneWestern blot analysisTime-dependent mannerRaloxifene treatmentReceptor modulatorsBreast cancerPan-caspase inhibitor zVADRaloxifene
1998
The Conventional Transforming Growth Factor-β (TGF-β) Receptor Type I Is Not Required for TGF-β1 Signaling in a Human Prostate Cancer Cell Line, LNCaP
Kim I, Zelner D, Lee C. The Conventional Transforming Growth Factor-β (TGF-β) Receptor Type I Is Not Required for TGF-β1 Signaling in a Human Prostate Cancer Cell Line, LNCaP. Experimental Cell Research 1998, 241: 151-160. PMID: 9633523, DOI: 10.1006/excr.1998.4034.Peer-Reviewed Original ResearchMeSH KeywordsActivin Receptors, Type IDihydrotestosteroneGene ExpressionHumansMaleProstatic NeoplasmsProtein Serine-Threonine KinasesReceptor, Transforming Growth Factor-beta Type IReceptor, Transforming Growth Factor-beta Type IIReceptors, Transforming Growth Factor betaRNA, MessengerSensitivity and SpecificitySignal TransductionTransforming Growth Factor betaTumor Cells, CulturedConceptsHuman prostate cancer cell linesCompetitive quantitative RT-PCRProstate cancer cell linesType II receptorLNCaP cellsII receptorsWestern blot analysisQuantitative RT-PCRCancer cell linesTGF-beta signalingALK-5RT-PCRALK-1Androgen-responsive human prostate cancer cell lineGrowth factor-β receptor type IType II receptor mRNAReceptor type IConcentrations of dihydrotestosteroneTGF-β1 signalingCell linesBlot analysisType INM dihydrotestosteroneReceptor mRNADihydrotestosterone
1995
Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone
Lee C, Sutkowski D, Sensibar J, Zelner D, Kim I, Amsel I, Shaw N, Prins G, Kozlowski J. Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone. Endocrinology 1995, 136: 796-803. DOI: 10.1210/en.136.2.796.Peer-Reviewed Original ResearchProstate-specific antigenProduction of prostate-specific antigenProstate-specific antigen secretionConcentrations of dihydrotestosteroneEffects of androgensDihydrotestosterone concentrationsAndrogen receptorAndrogen-sensitive human prostate cancer cell lineAndrogen-sensitive prostate cancer cellsIncreasing concentrations of DHTLow concentrations of dihydrotestosteroneCharcoal-stripped fetal bovine serumAnalysis of androgen receptorHuman prostate cancer cell linesProstate cancer cell linesCellular proliferationProstate cancer cellsNuclear androgen receptorAmount of receptor proteinDose-dependent inductionProportion of cellsFetal bovine serumCancer cell linesLNCaP cellsRegulation of proliferation